Abstract
PHYSICIANS and members of the public understand that each new drug must, at some point, be given to humans for the first time without confident knowledge of its effects and toxic potential. Although the ethics and constraints necessary for this testing have been discussed widely, there has been little attention given specifically to the first trials of new cancer chemotherapeutic agents (phase I trials). However, new cancer chemotherapeutic agents cannot be treated simply as new drugs; their toxic effects are often so much greater than those of other drugs that the clinical investigator must weigh many conflicting arguments to justify the trial. Referring physicians, in their role as advisors, are often called on to explain the trials and to counsel patients who may enter them. Thus, they should have full appreciation of the nature and ethics of such trials. A phase I clinical trial in patients with cancer does not
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
